-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4947 Effect of Consolidation with Allogeneic Hematopoietic Cell Transplant Versus No Consolidation in Patients with Non-Hodgkin Lymphomas Treated with Bispecific Antibodies

Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Hematology Disease Topics & Pathways:
Adult, Clinical Practice (Health Services and Quality), Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Diseases, Therapy sequence, Treatment Considerations, Lymphoid Malignancies, Study Population, Human
Monday, December 9, 2024, 6:00 PM-8:00 PM

Giulia Losi, MD1,2*, Marta Peña2*, David A. Qualls, MD3, Jennifer L. Crombie, MD4*, Jacopo Mariotti5*, Stefania Bramanti6*, Nicole Fabbri2,7*, Angel Serna, MD8*, Yasmina I.M. Serroukh9*, Aitana Balaguer Rosello, MD, PhD10*, Marjolein W.M. van der Poel11*, Ya-Ting Hsu12*, Ana Jiménez Ubieto13*, Christopher McKinnely14*, Philippe Armand, MD, PhD4, Felipe Peña, MD2*, Itziar Carro, MD2*, Carolina Martinez2*, Eva Domingo Domenech, MD2*, Patricia Lopez Pereira2*, Carolina Esther Arevalo Leon, MD2*, Eva Gonzalez Barca2*, Anna Sureda Balari2,15 and Alberto Mussetti2*

1Department of Molecular Medicine, University of Pavia, Pavia, Italy
2Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA
5Bone Marrow Transplantation and Cell Therapy Unit, Humanitas Clinical and Research Center, Rozzano, Italy
6IRCCS Humanitas Research Hospital, Transplantation Unit Department of Oncology and Haematology, Milan, Italy, Rozzano, Milano, Italy
7Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy
8Hematology Department, Hospital Universitario Vall d’Hebron, Barcelona, Spain
9Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Leuven, Belgium
10Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain
11Department of Internal Medicine, Division of Hematology, GROW school for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, Netherlands
12Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, Taiwan, TWN
13Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
14Haematology Department, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
15University of Barcelona, Bellvitge Health Sciences Campus, Barcelona, Spain

Background: Bispecific antibodies (BsAb) are an effective salvage therapy for relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHL). Patients (pts) achieving partial (PR) or complete response (CR) with BsAbs can experience prolonged duration of response, raising questions about the role of allogeneic hematopoietic cell transplantation (HSCT) as consolidation after BsAbs. Our aim is to compare the impact of HSCT consolidation in pts treated with BsAb versus a non-consolidation strategy.

Methods: We conducted a multicentric, retrospective study including adult pts with R/R B-NHL treated with BsAbs as last line of therapy and consolidated with HSCT. A control cohort of adult pts with R/R B-NHL treated with BsAbs who did not receive HSCT from a single institution was used. All pts received BsAb from April 2016 to July 2024 and had at least 3 lines of therapy before BsAb administration. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), non-relapse mortality (NRM) and relapse incidence/progression of disease (Rl/POD). The analysis started from the day of administration of the first dose of BsAb. A preplanned subanalysis for pts who reached PR/CR during BsAbs treatment was performed.

Results: Seventy-eight pts were enrolled. Forty-one (52.6%) pts received HSCT consolidation as per physician decision. The two groups (HSCT versus no consolidation) significantly differed in median age at BsAb administration (57 [range 22-71] vs 69 years [range 38-82], p=0.001), primary refractory disease (16 [39.0%] vs 8 [21.6%], p=0.001), prior administration of chimeric antigen T-cell receptor (20 [48.8%] vs 1 [2.7%], p<0.001), number of median lines at which BsAb was administered (4 [range 3-11] vs 3 [range 3-12], p=0.001) and type of administered BsAb (glofitamab 21 [51.2%] vs 17 [45.9%], epcoritamab 7 [17.1%] vs 20 [50.4%], mosunetuzumab 1 [2.4%] vs 0, ondronextamab 11 [26.8%] vs 0, BsAb antiCD22-CD3 1 [2.4%] vs 0, p<0.001). Median duration of BsAb treatment was 4.4 months (range 1.4-10.8) vs 3.5 months (range 0-48.4, p=0.620). Median number of BsAb administered doses was 12 (range 4-24) vs 11 (range 1-68)(p=0.394).

Of the 41 pts who proceeded to HSCT consolidation, 36 (87.8%) were in CR, 4 (9.8%) in PR and 1 (2.4%) in progressive disease (PD) before transplant. Median time from last BsAb dose to HSCT was 35 days (range 13-203). Type of donor was matched unrelated in 16 (39.0%), haploidentical in 16 (39.0%) and matched related in 9 (22.0%) pts. Thirty-eight (91.7%) pts received reduced intensity conditioning protocols, and 30 (73.2%) received post-transplant cyclophosphamide as graft-versus-host-disease prophylaxis.

Of the 37 pts who did not receive HSCT, overall response rate was 54% (n = 20) (CR rate 48.6% [n = 18]). Eight (21.6%) pts received a fixed number of doses of BsAb as per protocol. Early discontinuation of BsAb occurred in 25/29 pts (86.2%): 15 (40.5%) due to RI/POD, 8 (21.6%) due to toxicity and 2 (5.4%) due to other causes. Four pts (10.8%) had ongoing treatment at analysis. All grade cytokine release syndrome occurred in 18 pts (48.6%) with all being grade 1 or 2. All grade immune effector cell-associated neurotoxicity syndrome occurred in 2 pts (< grade 3). The median time to best response was 41 days (range 27-166). Median duration of best response was 23.1 months (range 0.9-77).

Median follow-up among survivors from the whole series was 20.6 months (22.3 months[range 4.6-86.4] for the HSCT cohort vs 16.6 months [range 0.7-76.8] for the not consolidated group). At 1-year, no differences were observed in univariate analysis in terms of PFS (61.8% vs 53.8%, p=0.077), OS (85.2% vs 59%, p=0.266) and NRM (15.9% vs 2.8%, p=0.122) among HSCT and no-consolidation cohorts. A lower RI/POD was observed in the HSCT group (8.5% vs 43.3%, p<0.001). In the subanalysis including only pts achieving PR/CR before HSCT (n=40) or during BsAb treatment without consolidation (n=20), no differences in terms of PFS (60.7 vs 84.7%, p=0.379), OS (84.8% vs 90%, p=0.437) and RI/POD (8.7% vs 15.3%, p=0.228) were found. However, a higher NRM was observed after HSCT(13.4% vs 0%, p=0.026).

Conclusions: HSCT consolidation does not seem to be associated with improved survival outcomes, especially for pts reaching a PR or CR during BsAb treatment. These results should be confirmed in a larger study population with a prolonged follow-up.

Disclosures: Qualls: Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees. Crombie: Genentech/Roche: Research Funding; ADCT: Consultancy; Genmab/Abbvie: Consultancy; Bayer: Research Funding; Genentech: Consultancy; Regeneron: Consultancy; Seagen: Consultancy; Abbvie: Research Funding; Merck: Research Funding. Serna: AbbVie: Honoraria; Incyte: Honoraria; Roche: Honoraria; Astrazeneca: Honoraria; Janssen: Honoraria. van der Poel: Takeda: Honoraria; Kite, a Gilead company: Honoraria. Jiménez Ubieto: Janssen: Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Speakers Bureau; Regeneron Pharmaceuticals, Inc.: Consultancy; Sandoz: Speakers Bureau; Lilly: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Incyte: Speakers Bureau; Kite-Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Armand: Merck: Consultancy, Research Funding; BMS/Celgene: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Genmab: Consultancy; Enterome: Consultancy; Genentech/Roche: Consultancy, Research Funding; ATB Therapeutics: Consultancy; Foresight: Consultancy; Regeneron: Consultancy; Kite: Research Funding; Adaptive: Research Funding; IGM: Research Funding; AstraZeneca: Research Funding. Domingo Domenech: Ideogen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bristol Myers Squibb-Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Gonzalez Barca: Janssen: Consultancy, Other: Travel funding, Speakers Bureau; AstraZeneca: Speakers Bureau; Roche: Speakers Bureau; Takeda: Speakers Bureau; Novartis: Consultancy; Beigene: Consultancy; Lilly: Consultancy; Incyte: Consultancy, Speakers Bureau; Abbvie: Consultancy, Other: Travel funding, Speakers Bureau; EUSAPharma: Consultancy, Other: Travel funding, Speakers Bureau; Kiowa: Consultancy, Speakers Bureau; Gilead: Consultancy. Sureda Balari: Bluebird: Membership on an entity's Board of Directors or advisory committees; Mundipharma: Consultancy; GSK: Consultancy, Honoraria, Speakers Bureau; EBMT: Other: President; GETH-TC: Other: President; Alexion: Honoraria; Roche: Honoraria, Other: Travel Expenses; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Research Funding, Speakers Bureau; Takeda Pharmaceutical: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel Expenses, Research Funding, Speakers Bureau. Mussetti: Gilead: Research Funding; SANOFI: Other: speaking and teaching; JAZZ PHARMA: Other: speaking and teaching; Atara, Takeda: Other: Participation in clinical trials (PI); Merck, Jazz Pharma: Other: Honoraria for advisory board activities; Takeda, BMS , Gilead, Sanofi: Other: Honoraria for lectures.

*signifies non-member of ASH